Inhibitor development in haemophilia B: an orphan disease in need of attention.
about
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitorsTreatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryTreatment for preventing bleeding in people with congenital bleeding disorders undergoing surgeryRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitorsNew developments in the management of moderate-to-severe hemophilia BFuture of coagulation factor replacement therapyAnimal models of hemophiliaAn interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B.Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database.Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXImmunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.Current and evolving features in the clinical management of haemophiliaImmune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.Immunomodulatory gene therapy in lysosomal storage disordersA zymogen-like factor Xa variant corrects the coagulation defect in hemophiliaBAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia BPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyRecombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialLong-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4.AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.Design and characterization of an APC-specific serpin for the treatment of hemophilia.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Successful treatment of canine hemophilia by continuous expression of canine FVIIa.Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.The CDC Hemophilia B mutation project mutation list: a new online resource.A role for thrombin in the initiation of the immune response to therapeutic factor VIII.Molecular testing for disorders of hemostasis.A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.Clinical advances in hemophilia management.Immune tolerance induction in haemophilia: evidence and the way forward.Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis.Joint WFH-ISTH session: issues in clinical trial design.Current management of hemophilia B: recommendations, complications and emerging issues.Obstacles and future of gene therapy for hemophilia.
P2860
Q24187069-D9CB69D5-954B-472F-9289-F40D21F4721BQ24188177-00FCB766-3200-4F80-AF29-CB661F3D4283Q24202459-87AF7CD0-4AC3-4F60-BC63-F002BDCB75BCQ24236388-D30C1D64-1D92-41A8-8CDA-64D26B4BD44FQ26751323-CED3BF5A-8A45-4630-9199-4E3A846994E1Q26820824-35630640-346E-421E-8AAF-DD923D15E13CQ27012571-63412E12-9A33-4B6F-83BE-53537315BAA5Q30429771-C643FE80-C483-4F67-AB47-D0AF42D7FBE7Q30655343-174414D7-3256-494D-BAB1-0BF1D9941D0CQ33608230-B9720106-9355-40AD-ABD5-A653440ED2CCQ33637062-2DE979E4-FF50-4189-8BA8-8A9EFF8485DAQ33708976-F71AFDD1-D0D2-4D8F-8F1C-3D41A9E9BA10Q33724236-BE23E8B5-AF2D-49A8-97EB-9DDCEB5DEDD9Q33859520-DBC3BFA6-60AC-4F37-A756-36C455D4C74BQ33946163-8B7B65B3-C072-4B20-96EE-BFD864B8C76DQ34149960-5EB63B74-5F62-43F2-9624-FEA840AF80E7Q34348566-873F660F-F974-4F7D-8170-61655C8FE95DQ34416394-F3B636E9-6E9E-4530-ACA1-F693C2C1C13CQ34737483-684E6278-E3F8-492C-A723-9F86873E5E7FQ34994506-757147A8-BDFF-4601-869A-A318A531E00CQ35023274-5E8D3978-CB0F-40CA-B6F1-90E5DA1C2127Q35153203-C7F49ADD-19A2-4FA3-B6B7-D35F3B6C5889Q36037525-3F190B0F-9EA0-4504-BD2C-DB0C5BBD730EQ36085401-6AF1209D-4308-4553-B9C4-541AB1710817Q36176667-A240B3CB-E230-4792-9AC6-E12FEAD90EB2Q36640081-D95487CA-89FF-43C6-A9A4-25E36A66174BQ37162830-5BC11D4E-949D-4695-B681-460393A7AF11Q37342834-7DE6F2BA-39C8-4503-8A23-B0550D79E912Q37398119-74DEA4F1-4B5A-4B7B-AE10-B1B84F2B4039Q37428002-9372B68B-B353-4ABE-81AD-9AA5D980CC07Q37602557-54215FBF-9594-4326-AA4F-EAB91FF9CE79Q37868730-B62CC813-A6ED-47BB-B62E-3D7345E5CDE9Q37900933-47A8D879-A7A2-4213-9A19-B9A3B9B79F82Q37903944-C8CA9860-4951-4837-899D-E14E4F49BC1CQ38056462-60C4256E-75C0-42C3-9EB8-4A5FCD80732CQ38060224-B5AC4123-C7FE-4A63-8890-3002640C670AQ38114123-B4BD94E1-B43D-4BB8-B7D3-5CD25168F713Q38206863-BD9B3995-8D1C-4B14-875A-1CB2BA0A3F6BQ38238972-49157A98-E953-404C-B556-424C8DCD12F7Q38529941-0178896C-9985-482C-AA99-AF36A99B6C2E
P2860
Inhibitor development in haemophilia B: an orphan disease in need of attention.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Inhibitor development in haemophilia B: an orphan disease in need of attention.
@en
type
label
Inhibitor development in haemophilia B: an orphan disease in need of attention.
@en
prefLabel
Inhibitor development in haemophilia B: an orphan disease in need of attention.
@en
P2860
P921
P1476
Inhibitor development in haemophilia B: an orphan disease in need of attention.
@en
P2093
Donna DiMichele
P2860
P304
P356
10.1111/J.1365-2141.2007.06657.X
P407
P577
2007-08-01T00:00:00Z